Danbury-based MannKind says an early clinical trial of its inhaled treatment for idiopathic pulmonary fibrosis met its main goal. The company reported that the treatment was generally safe and well tolerated by patients in the study. The trial did not establish whether it improves their condition. Mayor Roberto Alves praised the company’s work in Danbury, where MannKind develops and manufactures medicines.